YY1

5 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

2 independent labs in 2 countries
1 finding against

Funders: National Center for Advancing Translational Sciences and 2 more

Humans1
Animals3
Cells1

Effects

Cellular senescence

upin human cells1downin mice1

2 studies

YY1 protects against cellular senescence in mice.
“These cells displayed reduced quiescence, elevated reactive oxygen species, increased mitochondrial oxidative capacity, and enhanced β-galactosidase activity-hallmarks of cellular aging.”
AnimalsYy1 REPO domain knockout (Yy1 -/ΔREPO)hematopoietic stem cells
YY1-Mediated Polycomb Group Function Safeguards Hematopoietic Stem Cells from Premature Aging
bioRxiv : the preprint server for biology29 Jan 2026Preprint
YY1 activates cellular senescence in human cells.
“Overall, we demonstrate that lactylated YY1 promotes fibroblast senescence and collagen deposition by activating the PU.1-BTG2 axis.”
Cells
YY1 lactylation promotes fibroblast senescence by targeting the PU.1-BTG2 axis to promote oral submucous fibrosis
Chemico-biological interactions30 Aug 2025